440 related articles for article (PubMed ID: 27364962)
1. Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.
Xu Y; Zhang Y; Quan Z; Wong W; Guo J; Zhang R; Yang Q; Dai R; McGeer PL; Qing H
Neurochem Res; 2016 Oct; 41(10):2788-2796. PubMed ID: 27364962
[TBL] [Abstract][Full Text] [Related]
2. Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of α-Synuclein.
Teng Y; Zhao J; Ding L; Ding Y; Zhou P
Molecules; 2019 Aug; 24(16):. PubMed ID: 31416122
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin Gallate Destabilizes α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface.
Yao Y; Tang Y; Wei G
ACS Chem Neurosci; 2020 Dec; 11(24):4351-4361. PubMed ID: 33186020
[TBL] [Abstract][Full Text] [Related]
4. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
[TBL] [Abstract][Full Text] [Related]
5. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
6. The Aggregation Conditions Define Whether EGCG is an Inhibitor or Enhancer of
Sternke-Hoffmann R; Peduzzo A; Bolakhrif N; Haas R; Buell AK
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183378
[TBL] [Abstract][Full Text] [Related]
7. How oxidized EGCG remodels α-synuclein fibrils into non-toxic aggregates: insights from computational simulations.
Gonçalves PB; Palhano FL; Cordeiro Y; Sodero ACR
Phys Chem Chem Phys; 2023 Jul; 25(28):19182-19194. PubMed ID: 37431676
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
9. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
10. EGCG attenuates α-synuclein protofibril-membrane interactions and disrupts the protofibril.
Yang Z; Yao Y; Zhou Y; Li X; Tang Y; Wei G
Int J Biol Macromol; 2023 Mar; 230():123194. PubMed ID: 36623616
[TBL] [Abstract][Full Text] [Related]
11. GV-971 attenuates α-Synuclein aggregation and related pathology.
Yu Z; Yang Y; Chan RB; Shi M; Stewart T; Huang Y; Liu Z; Lan G; Sheng L; Tian C; Yang D; Zhang J
CNS Neurosci Ther; 2024 Feb; 30(2):e14393. PubMed ID: 37563872
[TBL] [Abstract][Full Text] [Related]
12. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
Wang R; Sun H; Ren H; Wang G
Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
[TBL] [Abstract][Full Text] [Related]
14. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
[TBL] [Abstract][Full Text] [Related]
15. Methionine oxidation in α-synuclein inhibits its propensity for ordered secondary structure.
Ponzini E; De Palma A; Cerboni L; Natalello A; Rossi R; Moons R; Konijnenberg A; Narkiewicz J; Legname G; Sobott F; Mauri P; Santambrogio C; Grandori R
J Biol Chem; 2019 Apr; 294(14):5657-5665. PubMed ID: 30755483
[TBL] [Abstract][Full Text] [Related]
16. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
Rutherford NJ; Moore BD; Golde TE; Giasson BI
J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of green tea extract (-)-epigallocatechin-3-gallate in a preformed fibril-induced mouse model of Parkinson's disease.
Shen J; Xie J; Ye L; Mao J; Sun S; Chen W; Wei S; Ruan S; Wang L; Hu H; Wei J; Zheng Y; Xi Z; Wang K; Xu Y
Neuroreport; 2024 Apr; 35(6):421-430. PubMed ID: 38526966
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein in Parkinson's disease: causal or bystander?
Riederer P; Berg D; Casadei N; Cheng F; Classen J; Dresel C; Jost W; Krüger R; Müller T; Reichmann H; Rieß O; Storch A; Strobel S; van Eimeren T; Völker HU; Winkler J; Winklhofer KF; Wüllner U; Zunke F; Monoranu CM
J Neural Transm (Vienna); 2019 Jul; 126(7):815-840. PubMed ID: 31240402
[TBL] [Abstract][Full Text] [Related]
19. Suppression, disaggregation, and modulation of γ-Synuclein fibrillation pathway by green tea polyphenol EGCG.
Roy S; Bhat R
Protein Sci; 2019 Feb; 28(2):382-402. PubMed ID: 30394624
[TBL] [Abstract][Full Text] [Related]
20. α-Synuclein aggregation and modulating factors.
Paleologou KE; El-Agnaf OM
Subcell Biochem; 2012; 65():109-64. PubMed ID: 23225002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
